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Background: The major cause of cervical intraepithelial neoplasia (CIN) is persistent infection with human
papillomavirus (HPV). Most CIN grade 2 and 3 lesions are treated with cone excision, although a substantial
proportion (6-50%) of CIN2-3 lesions will regresses spontaneously. Predictors for regression of CIN2-3 are
desirable in order to reduce this overtreatment.
Methods: In this prospective cohort study, 145 consecutive women with first-time onset CIN2-3 in
colposcopy-directed biopsies and standardized biopsy-cone excision interval were included. The genotype of the
high-risk human papillomaviruses (=hrHPV) and clinical factors including sexual behaviour, parity, contraception
and smoking were assessed. Patients were divided into two groups according to lesions containing HPV16
(hrHPV16+) and high-risk non-HPV16 (hrHPV16-) genotypes.
Results: Women whose partners consistently used condoms showed a significantly higher regression rate than
women using other types of contraception (53% versus 13%, p<0.0001). However, this effect was only seen in
hrHPV16- patients (73% regression rate versus 13%, p<0.0001). HrHPV16+ patients had a significantly higher
number of sexual partners and more current smokers compared to hrHPV16- patients. The regression rate was
not significantly different in CIN2-3 lesions containing HPV16 (hrHPV16+) versus hrHPV16- genotypes.
Conclusions: Heterogeneity among hrHPV genotypes excists. HPV-genotype analyses can identify women who
significantly increase their chance of regression by consistent condom use.
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Cervical intraepithelial neoplasia (=CIN) is the premalig-
nant condition of invasive cervical cancer caused by per-
sistent infection with HPV, which can be detected in
over 99% of high-grade CINs and cervical cancers [1,2].
HPV is the most common sexually transmitted agent
worldwide [3,4] and up to 80% of all women will be
infected with genital HPV during life [3,5]. Most infec-
tions clear within 1–2 years [6,7], but a minority of* Correspondence: jpabaak47@yahoo.com
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reproduction in any medium, provided the orwomen with high-risk HPV will develop CIN [8,9]. CIN
lesions are dynamic, which means they can progress to
invasive cancer, persist for many years or regress spon-
taneously [10,11], depending on the balance between
the virus and host factors such as the individual local
immune response [12,13]. Several risk factors for
development of CIN have been identified, including sex-
ual behaviour, parity, contraception type and smoking
[6,14-17]. However, there are only a few studies on re-
gression in relation to already established CIN and HPV
genotypes [13,18-20].
The standard treatment of punch-biopsy detected
high-grade CIN2-3 is cone excision, although only abouttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proportion (6-50%) of CIN 2–3 regress spontaneously
over time depending on diagnostic criteria and follow-
up time [10,11,18]. Cone excision is an invasive proced-
ure, carrying the risk of potential complications [22].
The most serious complication is cervical insufficiency
in a future pregnancy, leading to a higher risk of late
abortion and preterm delivery during the second and
early third trimester of pregnancy [23,24]. Furthermore,
current screening programs and conventional thera-
peutic guidelines lead to considerable and increasing
over-treatment of CIN [25]. Due to the lack of known
factors, which could predict or promote regression of
CIN 2–3, many women are treated unnecessarily with
cone excision, although many would have regressed
spontaneously within months [18,26].
Different hrHPV genotypes have different carcinogenic
potential. HPV16 is the most common hrHPV genotype
found in more than 50% of cervical cancers [27]. Fur-
ther, HPV16 is the most carcinogenic one with the
highest risk of CIN2-3 lesions progressing to invasive
cancer and a lower probability of regression compared
to other genotypes [13,28,29].
The aim of this prospective study was to examine po-
tential associations between hrHPV genotypes, regression
rate and clinical factors such as sexual behaviour, parity,
condom use and smoking in women with first-time
onset CIN2-3 and standardized long interval (median
16 weeks) between punch biopsy and cone excision [18].
Methods
The study has been approved by the Norwegian Regional
Ethical committee (#NR303.06), the Social and Health
Department (#07/3300) and the Norwegian Social
Science Data Service (#17185). All patients gave written
informed consent.
Gynecologic and pathology methods
Two hundred and fifty-four women aged 25–40 years,
who were referred to the gynecology outpatient clinic at
Stavanger University Hospital for evaluation of atyp-
ical cytological cervical smear between January 2007 and
December 2008, were consecutively included. Norwegian
guidelines for examination and reporting of atypical
cytology were followed: 1. Low grade Squamous Intra-
epithelial Lesion (LSIL) or 2. Atypical Squamous Cells
of Undetermined Significance (ASCUS) + hrHPV posi-
tivity, 3. Recurrences of hrHPV positive cervical smears,
4. Atypical Squamous Cells, can not rule out a High-
grade lesion (ASC-H) and 5. High Grade Squamous
Intraepithelial Lesion (HSIL).
One hundred and nine patients were excluded due to
various reasons (Figure 1). Follow-up consisted of at
least 3 visits to the gynecology outpatient clinic.At the 1st visit patient characteristics and clinical data
regarding age, number of sexual partners, age at first
sexual intercourse, sexual activity span (= interval be-
tween first sexual intercourse and age at study inclu-
sion), parity, contraception and smoking were registered.
A colposcopy was performed prior to punch biopsies
and endo-cervical curettage.
At the 2nd visit (week 7–9) a second colposcopy was
performed to detect any fast developing premalignant
mucosal changes in the transformation zone.
At the 3rd visit (between 12 and 24 weeks) patients'
use of contraceptives since the baseline visit was
assessed and interval between biopsy and cone excision
calculated. Consistent condom use was defined as those
women, whose partners used condoms for all instances
of sexual intercourse in the interval between biopsy and
cone excision. Finally, after a third colposcopy a cone
excision of the abnormal area was performed using a
loop electrosurgical excision procedure. Cone excision
after more than 16 weeks after punch biopsy was related
to patient delay.
According to standard operating procedures punch
biopsies and conisation material were fixed in 4% buf-
fered formaldehyde (24–48 h) at 20 °C and embedded in
56 °C paraffin. All fixed biopsies were carefully oriented
by using Eosin-mediated embedding, which allows
macroscopic identification of the epithelium and reduces
erroneous orientation of the biopsy in the paraffin block
and thereby tangential cutting.
The Norwegian national guidelines for histological
grading of cervical dysplasia recommend to follow the
CIN classification which classify low-grade dysplasia
or cervical intraepithelial neoplasia grade 1 (CIN1) as
equivalent to cytological LSIL. Moderate-dysplasia or
CIN2 and severe dysplasia/carcinoma in situ or CIN3 as
equivalent to cytological HSIL [30]. The diagnosis of
each CIN grade is based on well-defined histopatho-
logical criteria [31]. Standard Hematoxylin Erythrosin
Saffran (HES) sections were used for histological evalu-
ation and independently reviewed by two experienced
gynecological pathologists (EG, JB), who were blinded
for each other’s diagnosis. The proliferation marker Ki-
67 and the tumour suppressor protein p16 were used to
optimize the diagnoses [13,32]. Regression was defined
as a CIN2–3 diagnosis in the cervical biopsy and CIN1
or less in the subsequent cone.
HPV- analysis
DNA- material from all biopsies at inclusion was iso-
lated (E.Z.N.A.TM Tissue DNA Kit, Omega Bio-Tek,
Inc., Norcross, GA, USA). HPV analyses were performed
using Linear Array (LA) HPV Genotyping test (Roche
Molecular Systems, Roche Diagnostics, Mannheim,
Germany), which detects 37 different HPV genotypes.
Figure 1 Inclusion and exclusion criteria. Norwegian guidelines for histological examination of atypical cytology were followed: 1. Low grade
Squamous Intraepithelial Lesion (LSIL) + high-risk Human Papillomavirus (hr-HPV) or 2. Atypical Squamous Cells of Undetermined Significance
(ASCUS) + hr-HPV or 3. Recurrences of hr-HPV positive cervical smears or 4. Atypical Squamous Cells, cannot rule out a High Grade lesion (ASC-H)
or 5. High Grade Squamous Intrepithelial Lesion (HSIL). AIS denotes Adenocarcinoma in situ and Bx Biopsy.
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(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82
and IS39, which is a subtype of 82), 3 possible high-risk
(26, 53 and 66), 9 unclassified (55, 62, 64, 67, 69, 71, 83,
84 and 89) and 9 low-risk genotypes (6, 11, 40, 42, 54,
61, 70, 72 and 81) in addition to β-globin DNA as a cel-
lular control. The amplification step was performed
according to the Roche users’ manual as previously
described [13]. Two observers, using the Linear Array
HPV Genotyping Test Reference Guide, manually inter-
preted the LA HPV genotyping strips [13]. All HPV geno-
typing was done after the diagnostic part of the study and
had no influence on the follow up of the patients.
Patients were divided into two groups according to the
presence or absence of HPV16. The hrHPV16+ group
was positive for HPV16 genotype independent of other
genotypes, while the hrHPV16- group was negative for
HPV16 but positive for other high-risk genotypes.
Statistical analysis
SPSS, version 19 (SPSS Inc., Chicago, IL, USA) was used
for statistical analyses. Data are presented as median
with range unless otherwise stated. The Kolmogorov-
Smirnov test and visual inspection of plots were used
to test for normal distribution. Continuous data were
analysed by 2-sided t-test or Mann–Whitney U-test,
as appropriate.
Receiver operating curve (ROC) analysis (MedCalc
Software, Mariakerke, Belgium) was used to calculatecut-off values of the clinical factors: age at inclusion,
interval between biopsy and cone excision, age at first
sexual intercourse, number of lifetime partners and
sexual activity span according to regression versus non-
regression [33]. Chi-Square tests were performed to
compare categorical variables.
A binary logistic multivariate regression model was
applied to perform multivariate analyses. Probabilities
< 0.05 were considered as statistically significant.
Results
The study population consisted of 145 women with a
first-time onset atypical cytological smear and histologi-
cally proven CIN2-3. All patients were positive for high-
risk or possible high-risk HPV in the punch biopsy
(Table 1). No patient was lost to follow-up.
Genotyping revealed that 54 patients were hrHPV16+
and 91 patients hrHPV16-. The overall regression rate in
the study was 18%. The regression rate in the hrHPV16-
group (20%) was higher compared to the hrHPV16+
group (15%), but the difference was not statistically
significant. In an additional analysis comparing regres-
sion versus non-regression in single and multiple
hrHPV-genotypes infected lesions, the regression rates
were 22% and 11%, respectively, a none-significant dif-
ference (p=0.10).
When comparing the two groups in a univariate ana-
lysis, hrHPV16+ patients had a significantly higher num-
ber of sexual partners and more current smokers
Table 1 The different high-risk HPV genotypes are listed
in the left column. The right column contains the number
of patients with only one or multiple genotypes,
respectively
HPV genotype Number of patients with
one/multiple genotypes
16 32 / 22
18 6 / 4
31 12 / 8
33 9 / 4
35 4 / 4
39 0 / 5
45 3 / 1
51 2 / 1
52 7 / 0
58 4 / 0
26,53,56,59,66,68,73,82 11 / 6
Munk et al. Infectious Agents and Cancer 2012, 7:30 Page 4 of 9
http://www.infectagentscancer.com/content/7/1/30compared to hrHPV16- patients (Table 2). In a multi-
variate analysis both numbers of sexual partners and
smoking remained statistically different between groups
(p=0.006 and p=0.03, respectively). Age, interval between
biopsy and cone excision, distribution of CIN2 and
CIN3, parity, age at first sexual intercourse, sexual activ-
ity span and condom use were not significantly different
between the two hrHPV groups.
Among all women whose partners used condoms for
all instances they had intercourse between biopsy and
cone excision (= consistent condom use), the regression
rate was significantly higher compared to women using
other types of contraception or whose partners incon-
sistently used condoms (9/17, 53% versus 17/128, 13%).
However, although consistent condom use was asso-
ciated with a significantly higher regression rate in
the hrHVP16- group (73% versus 13%), this effect was
not seen in hrHPV16+ patients (regression rate 16% ver-
sus 15%). Clinicopathologic features between the 17
consistent condom users and other patients did not
differ significantly.
In hrHPV16- patients, age ≤15 years at first sexual
intercourse, was associated with a significantly lower re-
gression rate (4%) compared to patients with a sexual
debut >15 years (25%) (Table 3). However, in a multi-
variate analysis only consistent condom use remained
as a significant predictor for regression with an odds
ratio of 19 (95% C.I. 4–82, p< 0.0001). Other factors
such as age, interval between biopsy and cone excision,
single or multiple hrHPV infections, number of sexual
partners, sexual activity span, parity and smoking did
not significantly affect regression rate in the hrHVP16-
group (Table 3). In the hrHPV16+ group none of the
examined factors was significantly correlated to regres-
sion (Table 4).Discussion
This prospective study examined the influence of hrHPV
genotypes on the regression rate. Further, potential
interactions of hrHPV genotypes and clinical factors like
age, interval between biopsy and cone excision, single or
multiple hrHPV infections, number of sexual partners,
age at first sexual intercourse, sexual activity span,
parity, consistent condom use and smoking were evaluated.
The main finding was that consistent condom use sig-
nificantly increased the regression rate in HPV16-, but
not in hrHPV16+ lesions. Further, the number of sexual
partners was higher and current smoking was more
prevalent in hrHPV16+ than in hrHPV16- patients, with
both differences reaching statistical significance both in
univariate (Table 2) and multivariate analyses.
In the study population as a whole only consistent
condom use was significantly associated with higher
regression rates. However, the regression rate overall
was not significantly different between hrHPV16+ and
hrHPV16- patients.
HPV16 has been described as the genotype with the
highest carcinogenic potential, the highest risk for pro-
gression to CIN3 and cervical cancer and the highest
attribution to cervical cancer worldwide [29,34-36].
HPV16 infections also tend to last longer than infections
caused by other hrHPV types [6]. However, the current
study did not find a significantly lower regression rate in
hrHPV16+ versus hrHPV16- patients, which is in line
with previously published data [18,20,37]. There was
a relatively small (5%) difference in regression rate
between the two hrHPV-genotype groups investigated in
the current study. Based on a retrospective sample size
calculation a study of 906 patients per group would be
needed to detect this difference with a power of 80%.
A higher number of sexual partners in hrHPV16+
women has also been stated in other studies [19,38].
This could be explained by the fact that increased sexual
contact with new partners increases the risk of being
infected with HPV16 compared to other hrHPV geno-
types, as HPV16 is the most frequent genotype [35]. A
significant association between lower age at sexual debut
and lower regression rate was found in hrHPV16-
patients only.
Smoking is counted as a risk factor for CIN develop-
ment [6,17,39], but data on the effect of smoking in rela-
tion to HPV genotype are sparse. Previous studies have
shown that cotinine and nicotine metabolites, which
potentially have mutagenous effects on the cervical epi-
thelium, accumulate in the cervical mucus of active
cigarette smokers [40,41]. As current smoking was more
prevalent among hrHPV16+ patients, smoking could
potentiate the mutagenic effects of hrHPV16 resulting in
an increased risk of developing CIN. Another potential
explanation for the higher prevalence of smokers among








Regression 26 (18) 8 (15) 18 (20) 0.5
Non-regression 119 (82) 46 (85) 73 (80)
Age
(median, min.-max., years) 31 (25-41) 32 (25-41) 30 (25-41) 1.0
≤30 66 (45) 20 (37) 46 (51) 0.1
>30 79 (55) 34 (63) 45 (49)
Interval biopsy-cone
(median, min.-max., days) 113 (84-171) 107(84-154) 113 (84-171) 0.6
≤115 101 (70) 38 (70) 63 (69) 0.9
>115 44 (30) 16 (30) 28 (31)
CIN diagnosis
CIN2 26 (18) 7 (13) 19 (21) 0.2
CIN3 119 (82) 47 (87) 72 (79)
HPV genotype
Single 91 (63) 32 (60) 59 (65) 0.5
Multiple 54 (37) 22 (40) 32 (35)
Smoking
Yes 48 (33) 25 (46) 23 (25) 0.009
No 97 (67) 29 (54) 68 (75)
Number of sexual partners
1-9 67 (46) 16 (30) 51 (56) 0.002
>10 78 (54) 38 (70) 40 (44)
Parity
Yes 92 (63) 36 (67) 56 (62) 0.5
No 53 (37) 18 (33) 35 (38)
Age of first sexual intercourse
≤15 38 (26) 15 (28) 23 (25) 0.7
>15 107 (74) 39 (72) 68 (75)
Sexual activity span
≤13 64 (44) 21 (39) 43 (47) 0.3
>13 81 (56) 33 (61) 48 (53)
Condom use
Yes 17 (12) 6 (11) 11 (12) 0.9
No 128 (88) 48 (89) 80 (88)
1min.-max.: minimum, maximum.
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lifestyle combined with a higher-risk sexual behavior
[42]. Both more sexual partners and smokers among
hrHPV16+ patients could indicate that these risk factors
are related to lifestyle.
Data indicate that condom use can have a positive ef-
fect on CIN regression [33,37]. Condom use reduces the
repeated exposure of the cervical mucosa to HPV and
the directly immunosuppressive effect of semen on the
cervical epithelium. These factors strengthen the local
immune system against the HPV infection and may
promote CIN regression [43,44]. Another interestinghypothesis is that the latex of the condoms stimulates
a general immune response, which might be beneficial
in the clearance of HPV.
In hrHPV16- patients consistent condom use increased
the regression rate significantly compared to none con-
dom users. Additionally, age >15 years at first sexual
intercourse was associated with a significantly higher
likelihood of regression. None of the examined clinical
factors had any significant effect on the regression rate
in hrHPV16+ patients. This underlines the heterogeneity
among hrHPV genotypes and that hrHPV16+ CIN
lesions may behave differently compared to other hrHPV









(median, min.-max., years) 30 (25-41) 29 (25-41) 30 (25-41) 0.8
≤30 46 (50) 10 (22) 36 (78) 0.6
>30 45 (50) 8 (18) 37 (82)
Interval biopsy-cone
(median, min.-max., days) 113 (84-171) 108 (84-127) 113 (84-171) 0.1
≤115 63 (69) 14 (22) 49 (78) 0.4
>115 28 (31) 4 (14) 24 (86)
CIN diagnosis
CIN2 19 (21) 5 (26) 14 (74) 0.4
CIN3 72 (79) 13 (18) 59 (82)
HPV genotype
Single 59 (65) 13 (22) 46 (78) 0.5
Multiple 32 (35) 5 (16) 27 (84)
Smoking
Yes 23 (25) 2 (9) 21 (91) 0.1
No 68 (75) 16 (24) 52 (76)
Number of sexual partners
1-9 51 (56) 11 (22) 40 (78) 0.6
>10 40 (44) 7 (18) 33 (82)
Parity
Yes 56 (62) 10 (18) 46 (82) 0.6
No 35 (39) 8 (23) 27 (77)
Age of first sexual intercourse
≤15 23 (25) 1 (4) 22 (96) 0.03
>15 68 (75) 17 (25) 51 (75)
Sexual activity span
≤13 43 (47) 11 (26) 32 (74) 0.2
>13 48 (53) 7 (15) 41 (85)
Condom use
Yes 11 (12) 8 (73) 3 (27) <0.0001
No 80 (88) 10 (13) 70 (87)
1min.-max.: minimum, maximum.
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ible to cofactors related to sexual behavior and consistent
condom use.
Heterogeneity of high-grade CIN related to HPV16
has previously been described in a study by Wentzensen
et al., which showed that hrHPV16+ lesions were asso-
ciated with lower mean age, worse colposcopic appear-
ance and a higher number of lifetime sexual partners
compared to hrHPV16- lesions [19].
As consistent condom use does not seem to affect
regression rate of hrHPV16+ CIN lesions in contrast to
hrHPV16- lesions, the behaviour and character of
HPV16 and the subsequent immune reaction could be
different compared to non-HPV16 high-risk genotypes.Recent studies have shown interesting results comparing
epithelial and immune biomarkers in HPV16+ lesions
versus HPV16- CIN2-3 lesions in relation to regression
or not [13,20,45].
A better understanding of the different behaviour of
HPV genotypes could contribute to a more individua-
lized follow-up and treatment of CIN2-3 patients than
today’s standard treatment with cone excision of all
CIN2-3 lesions.
Consistent use of condoms by the male partners of the
women as contraception was rather infrequent. How-
ever, the current results showing that consistent condom
use by sexual intercourse increases the chances for
regression significantly with an odds ratio of 19 in









(median, min-max, years) 31 (25-41) 31 (25-41) 31 (25-41) 0.9
≤30 20 (37) 1 (5) 19 (95) 0.1
>30 34 (63) 7 (20) 27 (80)
Interval biopsy-cone
(median, min-max, days) 113 (84-171) 107 (84-154) 113 (84-171) 0.1
≤115 38 (70) 6 (16) 32 (84) 0.7
>115 16 (30) 2 (12) 14 (88)
CIN diagnosis
CIN2 7 (13) 2 (29) 5 (71) 0.3
CIN3 47 (87) 6 (13) 41 (87)
HPV genotype
Single 32 (59) 7 (22) 25 (78) 0.08
Multiple 22 (41) 1 (5) 21 (95)
Smoking
Yes 25 (46) 5 (20) 20 (80) 0.3
No 29 (54) 3 (10) 26 (90)
Number of sexual partners
1-9 16 (30) 1 (6) 15 (94) 0.3
>10 38 (70) 7 (18) 31 (82)
Parity
Yes 36 (67) 6 (17) 30 (83) 0.6
No 18 (33) 2 (11) 16 (89)
Age of first sexual intercourse
≤15 15 (28) 2 (13) 13 (87) 0.8
>15 39 (72) 6 (15) 33 (85)
Sexual activity span
≤13 21 (39) 1 (5) 20 (95) 0.1
>13 33 (61) 7 (21) 26 (79)
Condom use
Yes 6 (11) 1 (16) 5 (83) 0.9
No 48 (89) 7 (15) 41 (85)
1min.-max.: minimum, maximum.
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tion of women and their partners to use condoms for a
limited time period.
The strength of the current study is the prospective
design and the histological definition of CIN regression.
The study population was relatively homogenous due to
the inclusion criterion of age between 25 and 40 and the
standardized interval between biopsy and cone excision.
Additionally, both CIN2/CIN3 and consistent condom
use was equally distributed across the two HPV groups.
All 145 patients had hrHPV positive DNA in the punch
biopsies by LA. This strengthens the diagnosis of the
current biopsies, and ensures the genotype of the actualHPV infection. Stavanger University Hospital is the only
hospital in the region, making this a population-based
cohort study with low selection bias.
The observational period of the study, however, was rela-
tively short in relation to the natural history of CIN. On
the other hand, a longer observational period of high-grade
CIN regression with the risk of progression could not have
been justified at the start of the study. With current data
new trials with a longer interval between punch biopsy
and cone excision are acceptable in women under 40 years
of age with a first time onset CIN2-3 lesion. Further, the
sample size is rather moderate, which limits the separate
interpretation of clinical factors in each group.
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In conclusion, consistent condom use significantly increased
the regression rate in hrHPV16- but not in hrHPV16+
lesions. This suggests different immunologic response,
and might have clinical impact, as HPV genotyping
can identify patients who would significantly benefit
from consistent condom use. Further heterogeneity is
expressed by a higher number of sexual partners and
more current smokers in hrHPV16+ patients.
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